

Haverford College

Haverford Scholarship

Faculty Publications

Biology

2021

Large-scale genomic analysis of antimicrobial resistance in the zoonotic pathogen *Streptococcus suis*

Nazreen F. Hadjirin

Eric L. Miller

Gemma G.R. Murray

Phung L.K. Yen

Ho D. Phuc

Follow this and additional works at: https://scholarship.haverford.edu/biology_facpubs

RESEARCH ARTICLE

Open Access



Large-scale genomic analysis of antimicrobial resistance in the zoonotic pathogen *Streptococcus suis*

Nazreen F. Hadjirin^{1*}, Eric L. Miller², Gemma G. R. Murray¹, Phung L. K. Yen³, Ho D. Phuc³, Thomas M. Wileman¹, Juan Hernandez-Garcia¹, Susanna M. Williamson⁴, Julian Parkhill¹, Duncan J. Maskell⁵, Rui Zhou⁶, Nahuel Fittipaldi⁷, Marcelo Gottschalk⁷, A. W. (Dan) Tucker¹, Ngo Thi Hoa³, John J. Welch⁸ and Lucy A. Weinert¹

Abstract

Background: Antimicrobial resistance (AMR) is among the gravest threats to human health and food security worldwide. The use of antimicrobials in livestock production can lead to emergence of AMR, which can have direct effects on humans through spread of zoonotic disease. Pigs pose a particular risk as they are a source of zoonotic diseases and receive more antimicrobials than most other livestock. Here we use a large-scale genomic approach to characterise AMR in *Streptococcus suis*, a commensal found in most pigs, but which can also cause serious disease in both pigs and humans.

Results: We obtained replicated measures of Minimum Inhibitory Concentration (MIC) for 16 antibiotics, across a panel of 678 isolates, from the major pig-producing regions of the world. For several drugs, there was no natural separation into 'resistant' and 'susceptible', highlighting the need to treat MIC as a quantitative trait. We found differences in MICs between countries, consistent with their patterns of antimicrobial usage. AMR levels were high even for drugs not used to treat *S. suis*, with many multidrug-resistant isolates. Similar levels of resistance were found in pigs and humans from regions associated with zoonotic transmission. We next used whole genome sequences for each isolate to identify 43 candidate resistance determinants, 22 of which were novel in *S. suis*. The presence of these determinants explained most of the variation in MIC. But there were also interesting complications, including epistatic interactions, where known resistance alleles had no effect in some genetic backgrounds. Beta-lactam resistance involved many core genome variants of small effect, appearing in a characteristic order.

Conclusions: We present a large dataset allowing the analysis of the multiple contributing factors to AMR in *S. suis*. The high levels of AMR in *S. suis* that we observe are reflected by antibiotic usage patterns but our results confirm the potential for genomic data to aid in the fight against AMR.

Keywords: Genotype to phenotype, Prediction model, Ecology, Beta-lactam resistance, Tiamulin, Trimethoprim, Pig

* Correspondence: nh396@cam.ac.uk

¹Department of Veterinary Medicine, University of Cambridge, Cambridge, UK

Full list of author information is available at the end of the article



© The Author(s). 2021 **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Background

The ability of bacterial pathogens to evolve resistance to antimicrobials is one of the gravest threats to human health and food security worldwide. Antimicrobial resistance (AMR) to a given drug can be quantified via the minimum inhibitory concentration (MIC), i.e. the minimum concentration of the drug that is sufficient to inhibit growth of a bacterial culture. While, for practical use, bacterial isolates are often categorised as either susceptible or resistant, MIC is a continuously varying trait (measured discontinuously). In this study, we investigate how AMR genes, variants and ecology explain antibiotic phenotype in the bacterium *Streptococcus suis*, treating MIC phenotype as a quantitative trait.

S. suis primarily exists as a commensal in pigs, colonising the nasopharynx, gut and vagina, but it also causes systemic and respiratory disease, particularly in young pigs [1]. *S. suis* is also a serious zoonotic disease, being the leading cause of adult bacterial meningitis in Vietnam [2]. While some autogenous vaccines are used in pig production, they are serotype-specific and give inconsistent cross protection against heterogeneous *S. suis* [3]. Antimicrobials therefore remain the standard treatment for *S. suis*, and as such, *S. suis* is a leading driver of antimicrobial usage in pig farms [4].

As well as being a serious problem in itself, *S. suis* also has unique benefits as a model for studying AMR. By weight, more pork is consumed globally than any other meat [5, 6], and *S. suis* is found in most, if not all, pigs [7]. Furthermore, antibiotic consumption is higher in pigs (172 mg per population corrected unit) than any other livestock (e.g. cattle (45 mg) and chicken (148 mg)) [8]. As a result, most *S. suis* lineages will experience antibiotics. These include not only antibiotics administered directly against *S. suis*, whether as a therapeutic, prophylaxis or metaphylaxis, but also, and perhaps more commonly, in response to many other bacterial infections and in limited countries as growth promoters [9, 10].

The strong selection pressure caused by widespread use of antimicrobials in pig farming is expected to give rise to AMR in *S. suis*. Consistent with this, several phenotypic studies show high MICs for each of the major classes of antibiotics in one or more *S. suis* collections [11–15]. In addition, there have been demonstrations of individual resistance determinants affecting MIC in *S. suis* [16–18], and also some mining of *S. suis* genome collections for known resistance determinants [19–21]. However, to our knowledge, no study has combined complete genomic and phenotypic information in large numbers of isolates, collected from a diverse range of populations.

To this end, we obtained replicated measures of MIC for 16 antibiotics, each widely used in pigs, for six different *S. suis* collections, comprising 678 isolates. These

collections were chosen to include the three main pig-producing regions of the globe—namely the Americas, South East Asia and Europe—and targeted both human and pig hosts, as well as a range of years, serotypes and clinical phenotypes [22–24]. We obtained whole genome sequences for each of our isolates, allowing us to compare phenotype and genotype on an unprecedented scale.

Results


Measurement of MIC for 16 antibiotics in *S. suis*

We scored 678 isolates of *Streptococcus suis* for replicated measures of Minimum Inhibitory Concentration (MIC) for 16 antibiotics (Additional file 1: Table S1). Four of these are beta-lactams (amoxicillin, cefquinome, ceftiofur and penicillin), which are typically used to treat *S. suis* infection in pigs. The other antibiotics are all widely used in the pig industry, but found in different drug classes. They comprise macrolide-lincosamide-streptogramin B (MLS_B: erythromycin, lincomycin, tilmicosin and tylosin), tetracyclines (doxycycline and tetracycline) and fluoroquinolones (enrofloxacin and marbofloxacin), plus one each of an aminoglycoside (spectinomycin), a pleuromutilin (tiamulin), trimethoprim (TMP) and a phenicol (florfenicol). Results, shown in the left-hand plot of Fig. 1, reveal wide variation among our isolates in MIC for most of the antibiotics. For a few antibiotics, especially the MLS_B and tetracyclines, the MIC values are clearly bimodal, suggesting a meaningful division between ‘resistant’ and ‘wild-type’ isolates. However, for most antibiotics, the distributions are either roughly lognormal (fluoroquinolones and phenicols) or positively skewed (spectinomycin, pleuromutilin, TMP and beta-lactams). It is striking that the distributions for the beta-lactams are not clearly dissimilar from any of the other antibiotic classes, despite their being the most common treatment against *S. suis*. Given these distributions, and the general lack of defined clinical breakpoints for these antibiotics in *S. suis* [25], we treated MIC as a quantitative trait in our subsequent analyses.

Ecological and genomic predictors of MIC

Our *S. suis* isolates were collected at different times, and from different countries, hosts and body sites, including sites associated with respiratory and systemic disease. Isolates were also genetically heterogeneous, and differed in their serotype; including serotypes with a known disease association (see ‘Methods’ and Additional file 1: Table S1). We first used linear models, to ask whether MIC levels varied systematically with these ecological and genomic factors.

S. suis is highly recombining, such that no single genealogy describes its diversity [22]. As such, to



characterise genomic diversity in our sample, we identified 30 BAPs clusters of similar strains (see ‘Methods’). Figure S1 shows a core genome phylogeny with these clusters highlighted (Additional file 2: Figure S1) [26–28]. The resulting clusters were a highly significant predictor of MIC ($p < 10^{-15}$; Table 1 (A)) showing that genomically similar isolates tend to have similar MIC values. To account for this genetic structure, ‘cluster’ was included as a random effect in subsequent analyses.

A model including all potential predictors showed that country of isolation was also a highly significant predictor of MIC. In addition, there were weaker effects of year of collection (with a slight trend for increasing MIC over time); for serotype (with non-disease-associated

serotypes tending to have higher MIC); and for host disease status (with non-clinical isolates having higher MIC) (Table 1 (B)).


Separate analyses for each antibiotic, showed that the effect of country was driven by consistently higher MIC in the samples from Canadian pigs. As shown in Fig. 2A (left-hand panel), this applied to 15/16 antibiotics, and also applied to various models (Table 1 (C)), and subsets of the data (Additional file 2: Figure S2). For example, the effect is seen consistently in systemic pathogens, respiratory pathogens and non-clinical isolates (Additional file 2: Figure S2). By contrast, the other predictors (year, serotype and clinical status) had effects that were less consistent or robust (Table 1 (D–F)). The difference in

Table 1 Ecological and genomic predictors of MIC

Analysis	#strains	Fixed effects	Df	F	p
(a)	678	Antibiotic	15	1404.125	$< 10^{-15}$
		genetic cluster	29	40.644	$< 10^{-15}$
(b)	450	Antibiotic	15	972.3107	$< 10^{-4}$
		Year	1	6.6078	0.0102
		Serotype	1	6.6261	0.0101
		Disease status	2	2.9760	0.0511
		Country	3	92.5155	$< 10^{-4}$
(c)	678	Antibiotic	15	1457.4043	$< 10^{-4}$
		Country	3	139.5902	$< 10^{-4}$
(d)	557	Antibiotic	15	1144.3846	$< 10^{-4}$
		Disease status	2	9.9619	$< 10^{-4}$
(e)	542	Antibiotic	15	1131.6347	$< 10^{-4}$
		Serotype	1	8.7216	0.0032
(f)	652	Antibiotic	15	1350.8781	$< 10^{-4}$
		Year	1	0.1591	0.69

the MIC values between Canada and the UK is consistent with higher antimicrobial usage reported in Canada [29, 30].

Predictions for Vietnam are more difficult, as there is a lack of official records of antibiotic usage, although it is likely that usage is both higher than in the EU and focussed on different drugs [31]. However, as shown in Fig. 2B (left-hand panel), we saw no such signal in the MIC data, even when we restricted the comparison to the genetic cluster BAPS4 that includes all of our Vietnamese sample (see ‘Methods’). The clearest pattern is for lower MIC for the MLS_B class in the Vietnamese isolates (pink points in Fig. 2B left-hand panel). As shown in Fig. 2C (left-hand panel), we also found no robust differences between Vietnamese isolates sampled from humans and pigs. This is consistent with pigs being a reservoir for this zoonotic disease, and the lack of evidence of genomic adaptation to human hosts [22].



Identification of candidate AMR determinants within *S. suis* genomes

Using a candidate locus approach, we next identified known and putative determinants of AMR that were present in our sampled genomes. We considered both the presence/absence of whole genes, and sequence variants within genes. In total, we detected 43 determinants: 10 completely novel variants of known resistance genes, 12 known resistance genes detected in *S. suis* for the first time, and 21 previously reported in *S. suis* (Table 2 and Additional file 1: Table S1). Our candidates come from three sources: the antimicrobial resistance database CARD [40], previously published *S. suis* variants not present in the CARD database [36, 38, 39] and novel variants detected using a subset of our data (see 'Methods').

Of the 10 novel determinants, six are variants in genes previously associated with resistance in other bacteria (including a promoter variant). In particular, we discovered four novel haplotypes within the loop region of the central transpeptidase domains of the *pbp2B* and *pbp2X* genes and within the signal peptide region of the *mraY* gene (encoding the enzyme, acetylmuramoyl-pentapeptide-transferase, essential to cell wall biosynthesis) that were associated with variation in beta-lactam MIC (Table 2). In particular, we noted a PBP2X mutation at the conserved location T551, similar to that found in *S. pneumoniae* (T550), group B streptococci (T555) and *S. pyogenes* (T553) PBP2X proteins [41] indicative of a shared overall mechanism mediating beta-lactam resistance across the genus. Polymorphisms in *mraY* have also been identified in a genome-wide association study of beta-lactam resistance in *S. pneumoniae* [42]. In addition to these four beta-lactam haplotypes, two variants – a variant of the chromosomal dihydrofolate reductase gene *dhfr* and its promoter – were associated with reduced susceptibility against trimethoprim (Table 2). Furthermore, all of these six variants were independently associated with changes in MIC in at least seven different genetic clusters (Additional file 2: Table S2) implying that the association between these variants and MIC is either directly causal or compensatory to the causal variant [43].

The remaining four novel variants were whole genes with homologies to known resistance genes: three located on mobile genetic elements (MGEs) and one chromosomal (Table 2). Three novel aminoglycoside resistance genes, carried by isolates with high spectinomycin MIC, were identified based on aminoglycoside resistance determinant protein homologies. Although previously undescribed, we found homologues in other bacteria using a *blastn* search of the non-redundant database in GenBank (Table 2). We also characterised a chromosomally-encoded *vgaC* homologue (37% protein

homology to *vgaC*), encoding an ABC-F ATP-binding cassette ribosomal protection protein, that we designate *vgaF*. This gene has arisen in 13 different BAPS clusters, each time associated with reduced susceptibility to tiamulin (Additional file 2: Table S2).

The 12 previously known AMR genes detected in *S. suis* for the first time are mobile genetic element (MGE)-linked genes that confer resistance to aminoglycosides (2/12), MLS_B (2/12), tetracyclines (5/12), TMP (2/12) and phenicol (1/12). Based on the CARD and NCBI databases, these genes are associated with other gram-positive and gram-negative bacteria (Table 2).

Overall, most of our candidate determinants (28/43) were found in fewer than 5% of the isolates, but *ermB* (which confers resistance to the MLS_B class) and *tetO* (which confers resistance to tetracyclines) were present in a majority of the isolates (Table 2). Only about a quarter of isolates carry a candidate determinant for the beta-lactams highlighting the continuing susceptibility to these first line treatment drugs in *S. suis*.

Nevertheless, as shown in Fig. 3, many isolates carried multiple determinants, and multidrug resistance was widespread. Around 40% of isolates carried resistance determinants to three or more classes of drug (275/678), and over 10% carried resistance determinants to five classes (81/678); this is more than carried no determinants at all (59/678).

Candidate AMR determinants explain most of the variation in MIC

We next investigated how well our candidate variants explain the variation we observe in MIC (see Additional file 2: Figures S3-S9 for detailed plots). The right-hand panel of Fig. 1 compares the distribution of MIC values for isolates carrying one or more of the candidate AMR determinants for that antibiotic class (denoted '1+'), to the MIC of the remaining isolates, which carry no such determinant (denoted '0').

The proportion of the variation in MIC explained by our variants varied between antibiotics. Explanatory power was strongest ($r^2 > 0.75$) for antibiotics where the distributions of MIC were most clearly bimodal (MLS_B and tetracyclines). By contrast, we found no association between our variants and MIC for the fluoroquinolones and phenicol, where the distribution of MIC values was roughly lognormal, consistent with our isolates representing a 'wild-type' population. For the remaining antibiotics, our determinants had intermediate explanatory power (Fig. 1), but there were very few isolates with high MIC that did not carry a candidate determinant. This suggests that we have detected most of the causal variants in our dataset, removing the need to perform additional genome-wide associations.

Table 2 AMR determinants of *Streptococcus suis*

AMR gene	Name in figures	Resistance conferred (Antibiotic Class)	No. of isolates in <i>S. suis</i>	Reported in other species (CARD and NCBI)	Reported genetic location in <i>S. suis</i> or other species
<i>ant(4)-b</i>	ant4lb	Aminoglycoside	1	This report	<i>Staphylococcus aureus</i> , <i>Staphylococcus epidermidis</i> , <i>Enterococcus spp.</i>
<i>ant(6)-Ia/aadE</i>	ant6la	Aminoglycoside	56	[21]	<i>Staphylococcus epidermidis</i> , <i>Streptococcus spp.</i> , <i>Enterococcus faecalis</i>
<i>ant(6)-b</i>	ant6lb	Aminoglycoside	12	This report	<i>Campylobacter spp.</i> , <i>Bacillus subtilis</i> , <i>Clostridium spp.</i>
<i>ant(9)-Ia/spw/aad9</i>	ant9la	Aminoglycoside	45	[21]	<i>Staphylococcus aureus</i> , <i>Enterococcus spp.</i> , <i>Staphylococcus spp.</i>
<i>aph(3)-IIIa</i>	aph3IIla	Aminoglycoside	46	[32]	<i>Campylobacter spp.</i> , <i>Staphylococcus spp.</i> , <i>Streptococcus spp.</i> , <i>Enterococcus spp.</i>
<i>ant1*</i>	ant1	Aminoglycoside	12	This report	<i>Campylobacter spp.</i> , <i>Clostridium difficile</i> , <i>Lactobacillus amylovorus</i>
<i>aadE1*</i>	aadE1	Aminoglycoside	2	This report	<i>Enterococcus faecium</i> , <i>Staphylococcus aureus</i>
<i>aadE2*</i>	aadE2	Aminoglycoside	5	This report	<i>Clostridium spp.</i> , <i>Campylobacter fetus</i>
<i>ermB</i>	ermB	MLS _B (Macrolide)/Lincosamide	370	[33]	<i>Campylobacter spp.</i> , <i>Clostridium spp.</i> , <i>Enterococcus spp.</i> , <i>Escherichia coli</i> , <i>Klebsiella pneumoniae</i> , <i>Proteus mirabilis</i> , <i>Shigella spp.</i> , <i>Staphylococcus spp.</i> , <i>Streptococcus spp.</i> , <i>Vibrio vulnificus</i> .
<i>ermG</i>	ermG	MLS _B (Macrolide)/Lincosamide	1	This report	<i>Clostridium difficile</i> , <i>Enterococcus faecium</i>
<i>ermT</i>	ermT	MLS _B (Macrolide)/Lincosamide	3	This report	<i>Enterococcus faecium</i> , <i>Staphylococcus aureus</i> , <i>Streptococcus spp.</i>
<i>mefA</i>	mefA	Macrolide	11	[33]	<i>Streptococcus spp.</i> , <i>Enterococcus faecium</i> , <i>Haemophilus parainfluenzae</i> , <i>Proteus mirabilis</i>
<i>mel/msD</i>	mel	Macrolide	9	[33]	<i>Streptococcus spp.</i> , <i>Enterococcus faecium</i> , <i>Haemophilus parainfluenzae</i> , <i>Proteus mirabilis</i> .
<i>InuB</i>	InuB	Lincosamide	3	[19]	<i>Enterococcus spp.</i> , <i>Staphylococcus spp.</i> , <i>Streptococcus agalactiae</i>
<i>linB</i>	linB	Lincosamide	42	[34]	
<i>InuC</i>	InuC	Lincosamide	9	[35]	<i>Campylobacter spp.</i> , <i>Clostridium difficile</i> , <i>Streptococcus agalactiae</i> .
<i>IsaE</i>	IsaE	Pleuromutilin	43	[19]	<i>Enterococcus spp.</i> , <i>Staphylococcus spp.</i> , <i>Streptococcus agalactiae</i> .
<i>tet44</i>	tet44	Tetracycline	4	This report	<i>Clostridium spp.</i>
<i>tetM</i>	tetM	Tetracycline	81	[21]	<i>Streptococcus spp.</i> , <i>Escherichia coli</i> , <i>Staphylococcus spp.</i> , <i>Enterococcus spp.</i> , <i>Klebsiella pneumoniae</i> , <i>Neisseria meningitidis</i> , <i>Clostridium difficile</i> , <i>Salmonella enterica</i>
<i>tetM1*</i>	tetM1	Tetracycline	34	This report	<i>Staphylococcus spp.</i> , <i>Streptococcus spp.</i> , <i>Enterococcus spp.</i> , <i>Bacillus spp.</i> , <i>Clostridium spp.</i>
<i>tetM2*</i>	tetM2	Tetracycline	43	This report	<i>Enterococcus spp.</i> , <i>Clostridium difficile</i> .
<i>tetM3*</i>	tetM3	Tetracycline	13	This report	<i>Streptococcus pneumoniae</i> , <i>Streptococcus pyogenes</i> , <i>Enterococcus spp.</i> , <i>Clostridium spp.</i>
<i>tetO</i>	tetO	Tetracycline	465	[21]	<i>Campylobacter spp.</i>
<i>tetO1*</i>	tetO1	Tetracycline	2	This report	<i>Dorea spp.</i> , uncultured bacterium
<i>tetW</i>	tetW	Tetracycline	8	[18]	<i>Streptococcus agalactiae</i> , <i>Clostridium difficile</i> , <i>Chlamydia trachomatis</i> .
<i>tet40</i>	tet40	Tetracycline	7	[19, 36]	<i>Clostridium difficile</i>

Table 2 AMR determinants of *Streptococcus suis* (Continued)

AMR gene	Name in figures	Resistance conferred (Antibiotic Class)	No. of isolates	Reported in <i>S. suis</i>	Reported in other species (CARD and NCBI)	Reported genetic location in <i>S. suis</i> or other species
<i>tetL</i>	tetL	Tetracycline	12	[21]	<i>Streptococcus spp.</i> , <i>Escherichia coli</i> , <i>Staphylococcus spp.</i> , <i>Enterococcus spp.</i> , <i>Klebsiella pneumoniae</i> .	Plasmid
<i>tet(O)/32(O)†</i>	tetO:W32: O	Tetracycline	20	[37]		ICE
<i>dfp</i>	dfp	TMP	11	This report	<i>Clostridium difficile</i> , <i>Enterococcus spp.</i> , <i>Staphylococcus aureus</i> , <i>Streptococcus agalactiae</i>	plasmid
<i>dfk</i>	dfk	TMP	7	This report	<i>Staphylococcus aureus</i> , <i>Staphylococcus epidermidis</i> .	plasmid
<i>vgaf*</i>	vgaf	Pleuromutilin	173	This report	Not known	Chromosome. Found as an intact gene (~1386 bp) or truncated (< 750 bp)
<i>cat*</i>	cat	Flofenicol	3	This report	<i>Enterococcus faecalis</i> , <i>Streptococcus iniae</i> , <i>Listeria monocytogenes</i> , <i>Staphylococcus aureus</i>	Plasmid, Transposon
<i>dhfr*</i>	DHFR102	TMP	235	This report	Mutations in I100L in <i>Streptococcus spp.</i> and <i>Staphylococcus aureus</i>	DHFR: I102L
<i>dhfr promoter*</i>	DHFR Promoter	TMP	86	This report	None reported	DHFR : A5G upstream/indels 0-30 bp upstream
<i>pbp2B/penA*</i>	PBP2B: hap	Penicillin	181	This report	Mutations in other locations in <i>Streptococcus pneumoniae</i> and Group B <i>Streptococcus spp</i>	PBP2B : K479T/A, D512E/Q/K/A, K513E/D,T515S
<i>pbp2X*</i>	PBP2X: hap	Ceftiofur	93	This report	None reported	PBP2X : M437L, S445T, T467S Y525F
<i>pbp2X</i>	PBP2X551	Penicillin	153	This report	Mutation in PBP2X in <i>S. pneumoniae</i> (T550), group B streptococci (T555) and <i>S. pyogenes</i> (T553)	PBP2X : T551S
<i>pbp2X</i>	PBP2X594: 596	Penicillin	15	[38]	<i>Streptococcus suis</i> . Mutations in other locations in <i>Streptococcus pneumoniae</i> , Group B <i>Streptococcus sp.</i> and <i>Streptococcus uberis</i>	PBP2X : L594Y/F, V596G
<i>pbp2X</i>	PBP2X569	Penicillin	10	[38]		PBP2X : N569Q
<i>mraY*</i>	MraY:hap	Penicillin	62	This report	None reported	MraY : M6/L and either A4S/T or G8S
<i>parC†</i>	ParC79	Fluoroquinolone	4	[39]	<i>Escherichia coli</i> , <i>Pseudomonas aeruginosa</i> , <i>Streptococcus spp.</i> , <i>Staphylococcus aureus</i>	ParC : S79
<i>gyrA†</i>	GyrA81	Fluoroquinolone	13	[39]	<i>Escherichia coli</i> , <i>Klebsiella spp.</i> , <i>Streptococcus spp.</i> , <i>Staphylococcus aureus</i>	GyrA : S81
<i>gyrA†</i>	GyrA85	Fluoroquinolone	1	[39]	<i>Escherichia coli</i> , <i>Klebsiella spp.</i> , <i>Streptococcus spp.</i> , <i>Staphylococcus aureus</i>	GyrA : E85

*Novel determinants reported in this study

† Not documented in the CARD database

MLS_B macrolide-lincosamide-streptogramin B, TMP trimethoprim




Fig. 3. High levels of multidrug resistance in *S. suis*. The upper panel shows the number of our 678 isolates that carry a given number of candidate AMR determinants. The low panel shows the number of isolates that carry one or more AMR determinant for a given number of drug classes. Results show that more isolates carry determinants against 5 drug classes than carry no determinant at all.

We next asked whether the variable presence of our candidate determinants in different ecological settings would explain the significant ecological predictors of MIC in our linear models (Table 1). Consistent with this hypothesis, the typical MIC level in each genetic cluster was highly correlated with the frequency of determinants in that cluster (Additional file 2: Figure S10).

Differences between countries were explained in the same way. The higher MIC in Canada than the UK was due to consistently higher frequencies of the same determinants (Fig. 2A right-hand panel)—with the exception of trimethoprim (see below). By contrast, tetracycline resistance throughout the BAPS4 cluster, though at similar levels in all three countries, was conferred by different determinants in Vietnam (Fig. 2B).

Ineffective variants and epistasis

While our data contained few isolates with high MIC that did not carry a candidate determinant, there were many isolates with low MIC despite carrying a determinant (Fig. 1).

In some cases, this was due to previously identified candidate genes that had no appreciable effect on MIC in our data. For example, spectinomycin MIC was unchanged by some determinants identified from the CARD database (e.g. *ant(6′)-Ib* in Additional file 2: Figure S7). If we allow for the presence of these non-functional genes, the r^2 value for spectinomycin increases from 0.37 (Fig. 1) to 0.69 (Additional file 2: Figure S11a).

In other cases, as is well known, variants act against only some of the antibiotics in a class. In MLS_B , for example, modification of the ribosomal target confers cross resistance to macrolides and lincosamides, while mechanisms such as efflux and enzymatic inactivation do not [44]; so *msrD* acts against erythromycin, but not against lincomycin, while *linB* inactivates lincomycin, but not erythromycin (Additional file 2: Figure S4). Again, taking this into account further increases predictive power (Additional file 2: Figure S11a).

As well as these simple cases, there were some clear examples of genetic interactions. For trimethoprim, two candidate variants—in the protein DHFR102 and its promoter (Table 2)—were found at higher frequency in the UK than Canada (Fig. 2A, right-hand-panel), but in Canada, the two variants were more often found together, leading to higher MIC overall (Fig. 2A; Additional file 2: Figure S9).

Finally, we observed complex patterns for the second most common determinant in our dataset, *ermB*. For the 334 isolates that carried only *ermB* (and no other candidate determinant to MLS_B class drugs), MIC values were clearly bimodal, with many carriers having very low MIC (Additional file 2: Figures S4 and S12). Further analysis revealed a small number of isolates with frameshift or premature stop codons (4/326 isolates with complete sequences in our assemblies). While the remaining isolates with low MIC carried rare amino acid variants at one of four positions (T75X, N100S, R118H and V226I)—the last three of which differentiate the *ermB* sequences

found in *Streptococcus pneumoniae* from *Clostridium perfringens* [45]. Nevertheless, no particular sequence was always associated with low MIC, suggesting some unidentified source of epistasis (see ‘Methods’ and Additional file 2: Figure S12 for full details).

Resistance to beta-lactams

While beta-lactams are the major treatment class for *S. suis*, it is notable that the explanatory power of our variants seems to be weaker for this drug class than for, e.g. tetracyclines or MLS_B.

In Streptococci, a typical route to beta-lactam resistance involves variants in the *pbp* genes, and it is well established that the joint action of many *pbp* variants is necessary to explain substantial changes in MIC [46, 47]. Single-point mutations in *pbp2x*, for example, cause very modest elevations in *S. pneumoniae* [46], group B Streptococci [48], *Streptococcus dysgalactiae subsp. equisimilis* [49] and *Streptococcus pyogenes* [41].


Like *S. pneumoniae*, *S. suis* has three key *pbp* genes, *pbp1A*, *pbp2b* and *pbp2x*, and shares a similarly broad MIC distribution (although with typically lower MIC values) [47, 50, 51]. Our data also show that mutations in *pbp2x* alone have small effects (Additional file 2: Figure S3), while genotypes carrying four or more variants have the highest mean MIC (Additional file 2: Figure S3). Our explanatory power increases greatly when we predict beta-lactam MIC from the total number of candidate variants carried (Additional file 2: Figure S11b).

Although official breakpoints are lacking for many beta-lactam antibiotics in *S. suis*, for penicillin, only the isolates with the most variants reach clinical significance (i.e. penicillin resistance ≥ 1 or $\log(0)$ MIC).

In *S. pneumoniae*, it has also been noted that mutations conferring resistance to beta-lactams occur in a set order, with amino acid changes in PBP2B and PBP2X often acting as the first step [46, 52, 53]. Figure 4 shows that our data also show this characteristic ‘nested’ pattern (see also Additional file 2: Figure S13 [28]);, with PBP2X mutations largely occurring in backgrounds containing PBP2B mutations and *MraY* mutations occurring in backgrounds containing both PBP2B and PBP2X mutations.

It is notable that mutations in *MraY*—which are generally last to occur, and never occur alone—might have a compensatory effect. Altered PBPs, while conferring resistance, might be less active transpeptidases than their wild-type counterparts [54]. For example, the amidotransferase enzyme encoded by *murT* enables cross-linking of cell wall peptidoglycans by preparing lipid II used by pneumococcal PBPs [55, 56]. Mutations in *MraY* might therefore compensate for reduced enzymatic activity of altered PBPs.

Studies have shown that cefotaxime, a third-generation cephalosporin like ceftiofur, selectively inactivates PBP2X but not PBP2B [57]. Our results echo this pattern because our PBP2B haplotype has a smaller change on mean MIC of ceftiofur than penicillin (Additional file



2: Figure S3), and the explanatory effects of our PBP haplotypes differ between the drugs (Fig. 1). Previous variants in PBP2X thought to confer cefuroxime resistance [38] and, while validated by our data, were only found at very low frequency in our collection (Table 2).

Discussion

We have examined antimicrobial susceptibility of *Streptococcus suis* to 16 antibiotics that are commonly used in pigs. Replicated measures of MIC suggest that, even when some isolates have very high MIC, there is often no natural separation into ‘resistant’ and ‘susceptible’ (Fig. 1). This highlights both the need for clinical breakpoints in *S. suis*, and the need to evaluate AMR with quantitative measurements of MIC. This is particularly important for beta-lactam resistance, given its multi-allelic nature (Fig. 4, Additional file 2: Figure S3), and the phenomenon of ‘MIC creep’ that may eventually lead to treatment failures (e.g. vancomycin resistance in MRSA in some regions [58, 59]).

We have also shown that AMR levels differ systematically between countries. For example, compared to the UK, Canada has consistently higher MICs, and frequencies of the same candidate AMR determinants (Fig. 2, Additional file 2: Figure S1). Differences in antimicrobial usage are the most plausible explanation for this trend, because usage is much higher in Canada than in the UK [29, 30]. In particular, the ban on antibiotics used as growth promoters came into effect in Canada only in 2018 versus 2006 in the UK. However, our results are correlational and other factors could be explanatory, e.g. different microbiome compositions in pigs from different areas.

Next, we have identified 43 candidate resistance determinants and shown that they explain the majority of the observed variation in MIC for 11/16 antibiotics, and a substantial fraction of the variation for a further 2/16 (Fig. 1).

While many of these variants were previously described, and most were found at low frequency (Table 2; Fig. 2), we detected three novel candidates that are common and associated with clinically relevant changes in MIC: *vgaF*, DHFR102 and the *dhfr* promoter. A new mechanism for tiamulin resistance, such as the *vgaF*, could have implications for treatment success because tiamulin is a common drug for treating infections in livestock, including pigs [60]. High-level trimethoprim resistance was associated with mutations in the promoter regions of the *dhfr* gene. This is in contrast to the *folA* (I100L), *folP* 1-2 codon insertion combination conferring high-level resistance to trimethoprim/sulfamethoxazole (TMS) in *S. pneumoniae* [61]. While our MICs were for trimethoprim, our observations suggest the evolution of divergent mechanisms of resistance against

TMS between these species. If these resistance mechanisms are functionally verified, they should be included in routine AMR gene testing for *S. suis*.

While our candidate variants were explanatory, we also found several complexities in the genotype-phenotype map. These include epistatic interactions, where the effects of some candidate genes vary with their *S. suis* genetic background. Phenotypic reversion (i.e. mutations in transcriptional regulators or elsewhere in the genome, counteracting a resistance determinant) can be common if resistance has a fitness cost [62]. In addition, resistance genes have been shown to be transcriptionally silenced [63]. These processes could explain why we see many isolates carrying candidate determinants but with low MIC (Fig. 1). This same pattern is also common in other bacteria and up to 10% of *S. aureus* isolates [64–68]. These complexities have consequences for diagnostic investigation of AMR of *S. suis* using whole genome sequences. While the predictive power is quite high for many antibiotics, we should expect many type I errors (false positives). These results also caution against using the presence of AMR determinants as a measure of resistance more generally.

While susceptibility to penicillin in clinical cases of *S. suis* remains high, we see substantial variation in beta-lactam MIC (Fig. 1A). Consistent with studies in other Streptococci, our results show incremental and ordered changes in amino acids, first within PBP2A and then PBP2X that lead to clinically relevant elevations in MICs. Accurate predictions of genotype-phenotype have already been developed in *S. pneumoniae* [47, 61, 69–71], group B Streptococci [72] and *S. pyogenes* [41]. With no effective treatment for *S. suis* other than antibiotics, developing similar models and monitoring of these variants in *S. suis* populations should be a priority.

Two final aspects of our results highlight the fact that while individual battles against AMR are effective, AMR is not always a problem that can be tackled one disease at a time.

First, we have found high levels of resistance in *S. suis* even to antibiotics that are not typically used to treat this infection, including high rates of multidrug resistance (Fig. 3). This trend could be partly due to the co-occurrence of resistance genes on MGEs. However, determinants for beta-lactams (found in 190/678 isolates)—which are the primary treatment—were less common than those for tetracyclines (574/678), MLS_B (395/678), trimethoprim (246/678) and tiamulin (193/678). This pattern probably reflects a ‘bystander selection effect’, common in opportunistic pathogens that are part of the healthy microbiota and frequently exposed to antibiotics used as therapeutics or growth promoters (although antimicrobial growth promoters are now banned in the UK, Vietnam and Canada). However, we note that

beta-lactams are prescribed at similar (if not higher frequencies) than many other drug classes in pigs making the pattern of fewer beta-lactam determinants particularly surprising.

Second, many of the rarer AMR genes in our sample were not previously known in *S. suis*, but are common in other bacteria, both gram negative and gram positive (Table 2). Together with the presence of non-typical Streptococcal *ermB* in some isolates, this raises the possibility of *S. suis* acting as a reservoir for AMR determinants in other bacteria. Indeed *S. suis* shares conserved chromosomal insertion sites with many human pathogens, such as *S. pyogenes*, *S. pneumoniae* and *S. agalactiae* [19]. Given that *S. suis* causes human clinical disease, a direct exchange of AMR genes between *S. suis* and other human pathogens is plausible. Our results lend further support to a one health approach to tackling AMR.

Conclusions

We present a comprehensive dataset comprising genomes, MIC and metadata allowing the first large-scale analysis of the multiple contributing factors to AMR in *S. suis*. Overall, the high levels of AMR that we observe are reflected by antibiotic usage patterns in pigs. First, *S. suis* is resistant to many classes of antibiotics that are not typically used to treat *S. suis* infection. Second, MIC and AMR determinant prevalence is significantly higher in Canada than the UK where antibiotic usage is lower. This indicates that the ongoing effort to reduce antimicrobial use in livestock worldwide may be effective for reducing AMR in *S. suis*. Our results also highlight some interesting complications in the genotype to phenotype map in *S. suis* but overall, the explanatory power we observe confirms the potential for genomic data to aid in the fight against AMR.

Methods

Streptococcus suis isolates

We assembled a collection of 678 *S. suis* isolates, including isolates from the UK ($n = 423$), Canada ($n = 205$) and Vietnam ($n = 50$) (Additional file 1: Table S1).

In the UK, isolates came from three different collections. The first collection in 2009–2011 sampled non-clinical and clinical isolates from pigs across England and Wales (described in Weinert et al. [22]). The second collection in 2013–2014 sampled non-clinical isolates from five farms (described in Zou et al. [24]). The third collection during 2013–2014 targeted clinical isolates from pigs across England and Wales (described in Wilman et al. [23]). In pigs that showed clinical symptoms consistent with *S. suis* infections (e.g. meningitis, septicaemia and arthritis), the site of isolation was classified as ‘systemic’ if recovered from systemic sites. The site of

recovery was classified as ‘respiratory’ if derived from lungs with gross lesions of pneumonia. *S. suis* isolates from the tonsils or tracheo-bronchus of healthy pigs or dead pigs without any typical signs of *S. suis* infections were defined as ‘non-clinical’. Isolates that could not confidently be assigned to these categories (e.g. a tonsil isolate from a pig with systemic signs) were classified as unknown. Altogether, the UK isolates were classified by clinical status as ‘systemic’ ($n = 94$), ‘respiratory’ ($n = 50$), ‘non-clinical’ ($n = 197$) or ‘unknown’ ($n = 82$), respectively.

The Canadian pig *S. suis* isolates from 1983 to 2016 were collected to target similar numbers of clinical and non-clinical isolates and were also classified by clinical status as ‘systemic’ ($n = 81$), ‘respiratory’ ($n = 30$), ‘non-clinical’ ($n = 55$) or ‘unknown’ ($n = 39$).

The Vietnamese isolates were collected to sample related populations from human and pig (described in Weinert et al. [22]). These comprised ‘systemic’ isolates ($n = 28$) from human clinical cases of meningitis from provinces in southern and central Vietnam, and ‘systemic’ ($n = 4$) or ‘non-clinical’ isolates ($n = 18$) from pigs, collected between 2000 and 2010. These isolates were exclusively serotype 2 or serotype 14 and belong to one genetic population (Additional file 1: Table S1).

Antimicrobial susceptibility testing

The minimum inhibitory concentrations (MIC) for a range of antibiotics were determined by the micro-broth dilution method, which was performed and the results interpreted in accordance with CLSI Approved Standards, M100-S25 (2015), Vet01S 3rd Edition (2015) and de Jong et al. [11, 73]. MIC measurements for some of our isolates were previously published [11]. For the remaining MIC measurements, the MICs were determined for sixteen different antimicrobial compounds, representing nine antimicrobial classes at LGC, Fordham, UK (formerly Quotient Bioresearch, Fordham, UK), for the UK and the Canadian isolates. MIC testing of antibiotics for the Vietnamese isolates was performed at the Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam, in collaboration with the Department of Veterinary Medicine, University of Cambridge, UK.

Whole genome sequencing, assembly and inference of population structure

Genome DNA extractions and whole genome sequencing of newly sequenced *S. suis* in this study were as previously described by Weinert et al. [22]. Briefly, single colonies of strains were grown up in broth culture, DNA was extracted using DNeasy kits (Qiagen), Illumina library preparations were performed as described by Quail et al. [74] and the whole genomes sequenced on the

HiSeq2000 according to the manufacturer's instructions (Illumina, San Diego, CA, USA) at the Wellcome Trust Sanger Institute, Cambridge, UK. Sequencing generated 125 bp paired end reads, which were assessed for quality using Sickle [75] after the removal of adapter sequences.

Sequencing reads that passed the quality threshold were put forward for de novo assembly generation using Spades v.3.10.1 [76] utilising a variety of parameters conditions. Our 678 isolates were combined with 401 additional genomes given in Additional file 3: Table S3 [27] to increase robustness of *S. suis* population structure estimation, although these isolates were unavailable for MIC testing. Draft genomes were annotated using Prokka v1.12-beta (v2.8.2) [77], and bacterial species assignment was performed by a combination of MLST assignment and FastQ Screen v.0.11.1 using a custom database [78]. We mapped the Illumina reads back to the de novo assembly to investigate polymorphic reads in the samples (indicative of mixed cultures) using BWA v.0.7.16a [79].

Genomes that exhibited poor sequencing quality (i.e. poor assembly as indicated by a large number of contigs (> 2.5% of the genome assembly in contigs less than 1 kb) an N50 value of less than 10 kb or a high number of polymorphic reads (> 2000 SNPs) or that which were inconsistent with an *S. suis* species assignment were excluded from the analysis.

In order to group our *S. suis* isolates into different genetic clusters, we used the programme hierBAPs in R [80, 81]. First, we inferred core genes from our isolates using Roary (v2.8.2) [82], aligned them using MACSE [83] and stripped regions that could not be aligned unambiguously due to high divergence, indels or missing data. This conserved region of the core genome was used as input in hierBAPs and to produce a consensus neighbour-joining phylogenetic tree using the K80 model in the R package *ape* (Additional file 2: Figure S1) [81, 84].

Known AMR determinant detection

ARIBA [85] identifies AMR determinants (or any sequence of interest) directly from paired sequencing reads using a public or custom reference database and relies on mapping the reads to reference sequence clusters followed by the formation of local assemblies of the mapped reads. The tool is further able to confirm the intactness of resistance genes to identify known or novel SNPs within a gene of interest.

The AMR determinants in *S. suis* were identified using ARIBA v2.10.0 based on the public AMR database, CARD [40], which was further supplemented with a custom database. The custom database contained gene sequences not present within the CARD database at the time of testing. These were previously published *S. suis*

AMR genes, single-nucleotide polymorphisms (SNPs) in genes known to confer antibiotic resistance and AMR genes found in other bacteria. In addition, we investigated whether there were additional novel resistance variants in known resistance genes (described below). The sequence identity threshold against a reference was set at 90%. Only paired end sequence reads that passed the quality control thresholds were used as input for ARIBA. To identify genes falling under the 90% identity threshold, we also performed blast searches of the draft assemblies against the non-redundant NCBI protein or nucleotide databases to identify variants or chimeric alleles of known resistance determinants that might not be present in the CARD database. Examples of allelic variants identified this way include *tet*, *aad*, *ant* and *cat* (Table 2).

Novel AMR candidate determinant detection

We identified novel resistance determinants by a range of methods. Candidate determinants that might encode novel resistance mechanisms were identified by scanning literature describing experimental studies and others found by genome-wide association studies (GWAS) in related bacterial species, for example, variants of *pbps*, *mraY*, *dhfr* and *folA* [46, 86–88] along with their promoter regions. To avoid over-fitting our generalised linear models, gene or promoters of interest in a 'training' subset of the collection ($n = 205$) were then extracted, aligned and ranked from the highest to lowest MIC values, using MUSCLE [89] in SEAVIEW [90]. Manual sequence analysis was then performed to identify either amino acid or nucleotide variations that associated with high MIC.

Kinetic and structural studies have previously established that beta-lactam resistance is conferred by substitutions within PBPs in *Streptococcus pneumoniae* [46, 91] and other streptococci [49, 92, 93]. While mutations are present throughout the entire PBPs, we noted statistically significant mutations (Additional file 2: Table S2) in altered PBP2B and PBP2X proteins in strains exhibiting high penicillin (≥ 1 mg/L) and ceftiofur MICs (≥ 2 mg/L), respectively. In PBP2B, the residue variations were present in loop regions, K479T/A, D512E/Q/K/A, K513E/D and T515S, within the *S. suis* transpeptidase domain (residues 351–681). In PBP2X, the mutations were located at positions M437L, S445T, T467S, Y525F and T551S, also in loop regions within its catalytic domain (residues 265–619). No statistically significant variations were found within PBP1A, although the variant P405T was shared by some of the BAP clusters. As multiple amino acid variants were identified within PBP2X and PBP2B, many of which were in the same genomic region (Table 2), we grouped the variants in to haplotypes. We did this by scoring haplotype presence if the

isolate had all of the amino acid variants associated with high MIC in a given gene.

In addition to allelic differences in PBP2B and PBP2X, we also detected mutations in *mraY*. Found immediately upstream of *pbp2X*, *mraY* encodes an acetylmuramoyl-pentapeptide-transferase enzyme which is essential to lipid cycle reactions in the peptidoglycan cell wall biosynthesis pathway. Residue substitutions were present at A4S/T, M6I/L and G8S within the signal peptide regions of the protein. These substitutions were in strong linkage disequilibrium, such that they almost always occurred in pairs. In particular, both A4S/T and G8S occurred only in isolates also carrying M6I/L, while M6I/L appeared alone in only a single isolate. As such, we scored each isolate as carrying the *mraY* determinant only if it carried two of these three amino acid substitutions (either A4S/T and M6I/L, or G8S and M6I/L; Table 2). This set of isolates differed significantly in their MICs in both penicillin and ceftiofur across multiple BAP groups (Additional file 2: Table S2).

Not all isolates with high tiamulin MICs possessed a *lsaE* gene, suggesting an additional mechanism in *S. suis* conferring resistance to pleuromutilins. Using the CARD RGI (resistance gene identifier) protein homology models, a *vgaC* homologue was identified as a candidate gene associated with variation in tiamulin MIC. The gene, designated as *vgaF* in this work, encodes an ABC-F ATP-binding cassette ribosomal protection protein and shares 37.14% homology to the reference. Located within the chromosome, *vgaF* is found intact (~1386 bp) in statistically significant numbers in isolates with MIC ≥ 8 mg/L (Additional file 2: Table S2) but is truncated (<750 bp) in others. Plasmid borne *vga* homologues including *vgaC* are frequently detected in staphylococci and have been shown to confer cross resistance to pleuromutilins, lincosamides and streptogramin A antibiotics. A chromosome based *vgaA* gene variant, encoding an ATP-binding cassette protein conferring resistance to streptogramin A and related antibiotics in *S. aureus*, has also been described [94].

An amino acid substitution (I102-L) was detected in the dihydrofolate reductase (DHFR) gene, *dhfr* (counterpart of *folA* in *S. pneumoniae*), in the majority of isolates with trimethoprim MICs of 0.12 mg/L or greater. Similar substitutions of isoleucine to leucine at position 100 in *S. pneumoniae* [87, 95] and *Streptococcus pyogenes* [96] is known to cause resistance to TMP. Additionally, we also identified polymorphisms within the promoter region (0–30 bp upstream) of the *dhfr* gene, an A5G substitution and insertions, in isolates exhibiting MICs ≥ 1 mg/L.

Mutations such as 1–2 codon insertions within *folP*, another core metabolic gene that is documented to confer resistance to trimethoprim/sulfamethoxazole in *S.*

pneumoniae, were also examined. While insertions and or deletions were absent, amino acid residue variations were observed at position 198 (A198G) either alone (9/678) or in combination with *dhfr* I102L (26/678 isolates) in isolates exhibiting a wide range of trimethoprim MICs; 0.03 mg/L–32 mg/mL. However, this data was not statistically significant in the Binomial sign tests and hence was excluded from further analysis.

All of these variants might be causal, compensatory or linked to high MIC because of population structure. We therefore examined our variants and showed that susceptible and resistance alleles were found repeatedly in different BAP clusters, which were significant using binomial sign tests when defining a cut-off (Additional file 2: Table S2).

The *pbp*, *mraY* and *vgaF* genes were unable to be included into the custom database in ARIBA because of the sequence divergence. Therefore, we manually aligned the genes in all 678 isolates using MUSCLE [89] in SEAVIEW [90].

Similarly, analysis for known variants in *gyrA* and *parC* were also performed by manually aligning the genes. The *tet(O/W/32/O)* gene was scored by using blastn because ARIBA was unable to differentiate mosaic sequence patterns

Serotype inference from whole genomes

Serotypes were determined in silico using the Athey et al. [97] serotype database, which we implemented in ARIBA. Failed ARIBA runs and sequence non-matches were designated as not available (NA).

Statistical analyses

All general linear models were fit in R v. 3.3 [98] using the built-in function *lm* for models with solely fixed effects, or via Reduced Maximum Likelihood, using the function *lme* from the package nlme v. 3.1-141 [99], when BAPs cluster was included as a random effect. The response MIC values were log transformed. Our data for host and country is confounded because all of our human samples came from Vietnam (human *S. suis* has a higher prevalence in South East Asia [37]). Therefore, we coded 'Country' as separate populations—Canada, UK, Vietnam-pig and Vietnam-human. We classified 'serotypes' into either disease-associated or non-disease associated according to Wileman et al. [23].

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s12915-021-01094-1>.

Additional file 1: Table S1. The 678 isolates in our collection with meta data, MIC values and candidate determinant presence/absence.

Additional file 2: Figures S1-S13 and Table S2. Fig S1 – Phylogenetic tree. **Fig S2** – MICs in Canada & the UK. **Fig S3** – The effects of candidate determinants on MIC for beta-lactams **Fig S4** – The effects of candidate determinants on MIC for MLSB. **Fig S5** – The effects of candidate alleles on MIC for tetracyclines. **Fig S6** – The effects of candidate alleles on MIC for fluoroquinolone. **Fig S7** – The effects of candidate alleles on MIC for the aminoglycoside, spectinomycin. **Fig S8** – The effects of candidate alleles on MIC for the pleuromutilin, tiamulin. **Fig S9** – The effects of candidate alleles on MIC for trimethoprim (TMP). **Fig S10** – Variation in the presence of candidate AMR determinants explains consistent differences between genetic clusters. **Fig S11** – Methods of using candidate determinants to predict MIC. **Fig S12** – Allelic variation in *ermB* and unidentified sources of epistasis. **Fig S13** – High levels of ‘nestedness’ suggest that resistance determinants to beta-lactams are acquired in a particular order. **Table S2** – Binomial tests showing that novel AMR variants are independently associated with MIC in different genetic clusters.

Additional file 3: Table S3 – The 401 additional isolates used to estimate population structure with their genetic BAPs cluster and their data availability.

Acknowledgements

We wish to thank Abiyad Baig, Andrew Balmer and Olivier Restif for helpful discussion on antimicrobial resistance in *S. suis*. In addition, we wish to acknowledge Chris Teale and three anonymous reviewers for improvements to the manuscript.

Authors' contributions

LAW and NTH conceived the study. AWT, SMW, RZ, MG, NF, JHG, TMW, JP and DJM contributed isolates. NFH, ELM, PLKY, HDP and NTH collected new data. NFH, ELM, GGRM, JJW and LAW analysed data. JJW produced all figures. LAW, NFH and JJW wrote the manuscript. All authors read and approved the final manuscript.

Funding

This work was primarily supported by a Challenge grant from the Royal Society (reference: CH160114) and an Isaac Newton Trust Research Grant (reference: 17.24(u)). In addition, LAW, ELM and GGRM were supported by a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (109385/Z/15/Z). We also acknowledge a BBSRC grant to AWT (BBSRC grant BB/L003902/1), a LoLa grant to DJM and AWT (BB/G019274/1) and a China MoST grant to RZ (2013DFG32360) for sample collections.

Availability of data and materials

Whole genome sequence assemblies are available from NCBI under Project ID PRJNA628943 [100]. The gene *cat* from isolate FX419 has accession [MT367165](#). The gene *aadE1* from isolate CF2D3-1A has accession [MT383663](#). The gene *aadE2* from isolate BH3D7-4E has accession [MT383664](#). The gene *ant1* from isolate CF2D3-1C has accession [MT383665](#). The gene *tetM* from isolate 1129711 has accession [MT383666](#). The gene *tetM* from isolate LSS85 has accession [MT383667](#). The gene *tetM* from isolate SS981 has accession [MT383668](#). The gene *tetO* from isolate D16-010262 has accession [MT383669](#). The gene *vgaF* from isolate 1230091 has accession [MT431628](#).

Declarations

Ethics approval and consent to participate

Bacterial isolates were collected from pigs by non-invasive sampling as part of wider preventive health programmes intended to control endemic diseases in the UK and Canada and therefore did not require ethical clearance. The collection of isolates from humans and animals in Vietnam was approved by the ethical committee of the Hospital for Tropical Diseases, HCMC (CS/ND/09/13) and the Sub Department of Animal Health of Ho Chi Minh City (1242/SNN-NN).

Consent for publication

All authors and funders have given their consent for publication.

Competing interests

The authors declare that they have no competing interests

Author details

¹Department of Veterinary Medicine, University of Cambridge, Cambridge, UK. ²Microbial Ecology and Evolution Laboratory, Haverford College, Haverford, USA. ³Oxford University Clinical Research Unit, Ho Chi Minh City, Vietnam. ⁴Department for Environment, Food and Rural Affairs (Defra), London, UK. ⁵Chancellery, University of Melbourne, Melbourne, Australia. ⁶College of Veterinary Medicine, Huazhong Agricultural University, Wuhan, China. ⁷Faculty of Veterinary Medicine, University of Montreal, Saint-Hyacinthe, Canada. ⁸Department of Genetics, University of Cambridge, Cambridge, UK.

Received: 10 May 2021 Accepted: 13 July 2021

Published online: 07 September 2021

References

- de Moor CE. Septicaemic infections in pigs, caused by haemolytic streptococci of new Lancefield groups designated R, S and T. *Antonie van Leeuwenhoek*. 1963;29(1):272–80. <https://doi.org/10.1007/BF02046069>.
- Wertheim HFL, Nguyen HN, Taylor W, Lien TTM, Ngo HT, Nguyen TQ, et al. *Streptococcus suis*, an important cause of adult bacterial meningitis in Northern Vietnam. *PLoS one*. 2009;4(6):e5973. <https://doi.org/10.1371/journal.pone.0005973>.
- Baums CG, Kock C, Beineke A, Bennecke K, Goethe R, Schröder C, et al. *Streptococcus suis* bacterin and subunit vaccine immunogenicities and protective efficacies against serotypes 2 and 9. *Clin Vaccine Immunol*. 2009; 16(2):200–8. <https://doi.org/10.1128/CVI.00371-08>.
- van Rennings L, von Münchhausen C, Ottillie H, Hartmann M, Merle R, Honscha W, et al. Cross-sectional study on antibiotic usage in pigs in Germany. *PLoS one*. 2015;10(3):e0119114. <https://doi.org/10.1371/journal.pone.0119114>.
- McGlone JJ. The future of pork production in the world: towards sustainable, welfare-positive systems. *Animals*. 2013;3(2):401–15. <https://doi.org/10.3390/ani3020401>.
- Steinfeld H, Gerber PJ, Wassenaar T, Castel V, Rosales M, De Haan C. *Livestock's long shadow: environmental issues and options 2006*.
- Goyette-Desjardins G, Auger J-P, Xu J, Segura M, Gottschalk M. *Streptococcus suis*, an important pig pathogen and emerging zoonotic agent—update on the worldwide distribution based on serotyping and sequence typing. *Emerg Microbes Infect*. 2014;3(1):1–20. <https://doi.org/10.1038/emi.2014.45>.
- Van Boeckel TP, Brower C, Gilbert M, Grenfell BT, Levin SA, Robinson TP, et al. Global trends in antimicrobial use in food animals. *Proc Natl Acad Sci U S A*. 2015;112(18):5649–54. <https://doi.org/10.1073/pnas.1503141112>.
- Spellberg B, Bartlett JG, Gilbert DN. The future of antibiotics and resistance. *N Engl J Med*. 2013;368(4):299–302. <https://doi.org/10.1056/NEJMp1215093>.
- Lekagul A, Tangcharoensathien V, Yeung S. Patterns of antibiotic use in global pig production: a systematic review. *Vet Anim Sci*. 2019;7:100058. <https://doi.org/10.1016/j.vas.2019.100058>.
- Hernandez-Garcia J, Wang J, Restif O, Holmes MA, Mather AE, Weinert LA, et al. Patterns of antimicrobial resistance in *Streptococcus suis* isolates from pigs with or without streptococcal disease in England between 2009 and 2014. *Vet Microbiol*. 2017;207:117–24. <https://doi.org/10.1016/j.vetmic.2017.06.002>.
- Yongkiettrakul S, Maneerat K, Arechanajan B, Malila Y, Srimanote P, Gottschalk M, et al. Antimicrobial susceptibility of *Streptococcus suis* isolated from diseased pigs, asymptomatic pigs, and human patients in Thailand. *BMC Vet Res*. 2019;15(1):5. <https://doi.org/10.1186/s12917-018-1732-5>.
- Marie J, Morvan H, Berthelot-Héralut F, Sanders P, Kempf I, Gautier-Bouchardon AV, et al. Antimicrobial susceptibility of *Streptococcus suis* isolated from swine in France and from humans in different countries between 1996 and 2000. *J Antimicrob Chemother*. 2002;50(2):201–9. <https://doi.org/10.1093/jac/dkf099>.
- Šeol B, Kelnerić Ž, Hajsig D, Madić J, Naglič T. Susceptibility to antimicrobial agents of *Streptococcus suis* capsular type 2 strains isolated from pigs. *Zentralbl Bakteriol*. 1996;283(3):328–31. [https://doi.org/10.1016/S0934-8840\(96\)80067-3](https://doi.org/10.1016/S0934-8840(96)80067-3).
- Turgeon PL, Higgins R, Gottschalk M, Beaudoin M. Antimicrobial susceptibility of *Streptococcus suis* isolates. *Br Vet J*. 1994;150(3):263–9. [https://doi.org/10.1016/S0007-1935\(05\)80006-5](https://doi.org/10.1016/S0007-1935(05)80006-5).
- Gurung M, Tamang MD, Moon DC, Kim S-R, Jeong J-H, Jang G-C, et al. Molecular basis of resistance to selected antimicrobial agents in the

- emerging zoonotic pathogen *Streptococcus suis*. J Clin Microbiol. 2015;53(7):2332–6. <https://doi.org/10.1128/JCM.00123-15>.
17. Yao J, Shang K, Huang J, Ran W, Kashif J, Wang L. Overexpression of an ABC transporter and mutations of GyrA, GyrB, and ParC in contributing to high-level ciprofloxacin resistance in *Streptococcus suis* type 2. Biosci Trends. 2014;8(2):84–92. <https://doi.org/10.5582/bst.8.84>.
 18. Hoa NT, Chieu TT, Nghia HD, Mai NT, Anh PH, Wolbers M, et al. The antimicrobial resistance patterns and associated determinants in *Streptococcus suis* isolated from humans in southern Vietnam, 1997–2008. BMC Infect Dis. 2011;11(1):6. <https://doi.org/10.1186/1471-2334-11-6>.
 19. Huang J, Ma J, Shang K, Hu X, Liang Y, Li D, et al. Evolution and diversity of the antimicrobial resistance associated mobilome in *Streptococcus suis*: a probable mobile genetic elements reservoir for other streptococci. Front Cell Infect Microbiol. 2016;6(118). <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053989/>
 20. Hu P, Yang M, Zhang A, Wu J, Chen B, Hua Y, et al. Comparative genomics study of multi-drug-resistance mechanisms in the antibiotic-resistant *Streptococcus suis* R61 strain. PLoS one. 2011;6(9):e24988. <https://doi.org/10.1371/journal.pone.0024988>.
 21. Holden MT, Hauser H, Sanders M, Ngo TH, Cherevach I, Cronin A, et al. Rapid evolution of virulence and drug resistance in the emerging zoonotic pathogen *Streptococcus suis*. PLoS one. 2009;4(7):e6072. <https://doi.org/10.1371/journal.pone.0006072>.
 22. Weinert LA, Chaudhuri RR, Wang J, Peters SE, Corander J, Jombart T, et al. Genomic signatures of human and animal disease in the zoonotic pathogen *Streptococcus suis*. Nat Commun. 2015;6(1):6740. <https://doi.org/10.1038/ncomms7740>.
 23. Wileman TM, Weinert LA, Howell KJ, Wang J, Peters SE, Williamson SM, et al. Pathotyping the zoonotic pathogen *Streptococcus suis*: novel genetic markers to differentiate invasive disease-associated isolates from non-disease-associated isolates from England and Wales. J Clin Microbiol. 2019;57(7):e01712–8.
 24. Zou G, Zhou J, Xiao R, Zhang L, Cheng Y, Jin H, et al. Effects of environmental and management-associated factors on prevalence and diversity of *Streptococcus suis* in clinically healthy pig herds in China and the United Kingdom. Appl Environ Microbiol. 2018;84(8):e02590–17.
 25. van Hout J, Heuvelink A, Gonggrijp M. Monitoring of antimicrobial susceptibility of *Streptococcus suis* in the Netherlands, 2013–2015. Vet Microbiol. 2016;194:5–10. <https://doi.org/10.1016/j.vetmic.2016.03.014>.
 26. Letunic I, Bork P. Interactive Tree Of Life (iTOL) v4: recent updates and new developments. Nucleic Acids Res. 2019;47(W1):W256–W9. <https://doi.org/10.1093/nar/gkz239>.
 27. Murray GGR, Charlesworth J, Miller EL, Casey MJ, Lloyd CT, Gottschalk M, et al. Genome reduction is associated with bacterial pathogenicity across different scales of temporal and ecological divergence. Mol Biol Evol. 2021;38(4):1570–9. <https://doi.org/10.1093/molbev/msaa323>.
 28. Lehtinen S, Blanquart F, Lipsitch M, Fraser C, with the Maela Pneumococcal Collaboration. On the evolutionary ecology of multidrug resistance in bacteria. PLoS Pathog. 2019;15(5):e1007763.
 29. Dunlop RH, McEwen SA, Meek AH, Black WD, Clarke RC, Friendship RM. Individual and group antimicrobial usage rates on 34 farrow-to-finish swine farms in Ontario, Canada. Prev Vet Med. 1998;34(4):247–64. [https://doi.org/10.1016/S0167-5877\(97\)00093-7](https://doi.org/10.1016/S0167-5877(97)00093-7).
 30. Directorate VM. UK veterinary antibiotic resistance and sales surveillance report. 2018.
 31. Carrique-Mas JJ, Choisy M, Van Cuong N, Thwaites G, Baker S. An estimation of total antimicrobial usage in humans and animals in Vietnam. Antimicrob Resist Infect Control. 2020;9(1):16. <https://doi.org/10.1186/s13756-019-0671-7>.
 32. Huang K, Zhang Q, Song Y, Zhang Z, Zhang A, Xiao J, et al. Characterization of spectinomycin resistance in *Streptococcus suis* leads to two novel insights into drug resistance formation and dissemination mechanism. Antimicrob Agents Chemother. 2016;60(10):6390–2. <https://doi.org/10.1128/AAC.01157-16>.
 33. Chang B, Wada A, Ikebe T, Ohnishi M, Mita K, Endo M, et al. Characteristics of *Streptococcus suis* isolated from patients in Japan. Jpn J Infect Dis. 2006;59(6):397–9.
 34. Bojarska A, Molska E, Janas K, Skoczynska A, Stefaniuk E, Hryniewicz W, et al. *Streptococcus suis* in invasive human infections in Poland: clonality and determinants of virulence and antimicrobial resistance. Eur J Clin Microbiol Infect Dis. 2016;35(6):917–25. <https://doi.org/10.1007/s10096-016-2616-x>.
 35. Athey TB, Auger JP, Teatero S, Dumesnil A, Takamatsu D, Wasserscheid J, et al. Complex population structure and virulence differences among serotype 2 *Streptococcus suis* strains belonging to sequence type 28. PLoS one. 2015;10(9):e0137760. <https://doi.org/10.1371/journal.pone.0137760>.
 36. Palmieri C, Magi G, Mingoia M, Bagnarelli P, Ripa S, Varaldo PE, et al. Characterization of a *Streptococcus suis* tet(O/W/32/O)-carrying element transferable to major streptococcal pathogens. Antimicrob Agents Chemother. 2012;56(9):4697–702. <https://doi.org/10.1128/AAC.00629-12>.
 37. Palmieri C, Varaldo PE, Facinelli B. *Streptococcus suis*, an emerging drug-resistant animal and human pathogen. Front Microbiol. 2011;2:235.
 38. Ge Y, Wu J, Xia Y, Yang M, Xiao J, Yu J. Molecular dynamics simulation of the complex PBP-2x with drug cefuroxime to explore the drug resistance mechanism of *Streptococcus suis* R61. PLoS one. 2012;7(4):e35941. <https://doi.org/10.1371/journal.pone.0035941>.
 39. Escudero JA, San Millan A, Catalan A, de la Campa AG, Rivero E, Lopez G, et al. First characterization of fluoroquinolone resistance in *Streptococcus suis*. Antimicrob Agents Chemother. 2007;51(2):777–82. <https://doi.org/10.1128/AAC.00972-06>.
 40. Jia B, Raphenya AR, Alcock B, Waglechner N, Guo P, Tsang KK, et al. CARD 2017: expansion and model-centric curation of the comprehensive antibiotic resistance database. Nucleic Acids Res. 2017;45(D1):D566–D73. <https://doi.org/10.1093/nar/gkw1004>.
 41. Vannice KS, Ricaldi J, Nanduri S, Fang FC, Lynch JB, Bryson-Cahn C, et al. *Streptococcus pyogenes* pbp2x Mutation Confers Reduced Susceptibility to β -Lactam Antibiotics. Clin Infect Dis. 2020;71(1):201–4. <https://doi.org/10.1093/cid/ciz1000>.
 42. Chewapreecha C, Marttinen P, Croucher NJ, Salter SJ, Harris SR, Mather AE, et al. Comprehensive identification of single nucleotide polymorphisms associated with beta-lactam resistance within pneumococcal mosaic genes. PLoS Genet. 2014;10(8):e1004547. <https://doi.org/10.1371/journal.pgen.1004547>.
 43. Albarracín Orió AG, Pinás GE, Cortes PR, Cian MB, Echenique J. Compensatory evolution of pbp mutations restores the fitness cost imposed by beta-lactam resistance in *Streptococcus pneumoniae*. PLoS Pathog. 2011;7(2):e1002000. <https://doi.org/10.1371/journal.ppat.1002000>.
 44. Leclercq R. Mechanisms of resistance to macrolides and lincosamides: nature of the resistance elements and their clinical implications. Clin Infect Dis. 2002;34(4):482–92. <https://doi.org/10.1086/324626>.
 45. Farrow KA, Lyras D, Polekhina G, Koutsis K, Parker MW, Rood JL. Identification of essential residues in the Erm(B) rRNA methyltransferase of *Clostridium perfringens*. Antimicrob Agents Chemother. 2002;46(5):1253–61. <https://doi.org/10.1128/AAC.46.5.1253-1261.2002>.
 46. Grebe T, Hakenbeck R. Penicillin-binding proteins 2b and 2x of *Streptococcus pneumoniae* are primary resistance determinants for different classes of beta-lactam antibiotics. Antimicrob Agents Chemother. 1996;40(4):829–34. <https://doi.org/10.1128/AAC.40.4.829>.
 47. Li Y, Metcalf BJ, Chochua S, Li Z, Gertz RE, Walker H, et al. Penicillin-binding protein transpeptidase signatures for tracking and predicting β -lactam resistance levels in *Streptococcus pneumoniae*. mBio. 2016;7(3):e00756–16.
 48. Dahesh S, Hensler ME, Van Sorge NM, Gertz RE Jr, Schrag S, Nizet V, et al. Point mutation in the group B streptococcal pbp2x gene conferring decreased susceptibility to beta-lactam antibiotics. Antimicrob Agents Chemother. 2008;52(8):2915–8. <https://doi.org/10.1128/AAC.00461-08>.
 49. Fuursted K, Stegger M, Hoffmann S, Lambertsen L, Andersen PS, Deleuran M, et al. Description and characterization of a penicillin-resistant *Streptococcus dysgalactiae* subsp. *equisimilis* clone isolated from blood in three epidemiologically linked patients. J Antimicrob Chemother. 2016;71(12):3376–80. <https://doi.org/10.1093/jac/dkw320>.
 50. Holmer I, Salomonsen CM, Jorsal SE, Astrup LB, Jensen VF, Høg BB, et al. Antibiotic resistance in porcine pathogenic bacteria and relation to antibiotic usage. BMC Vet Res. 2019;15(1):449. <https://doi.org/10.1186/s12917-019-2162-8>.
 51. Liñares J, Ardanuy C, Pallares R, Fenoll A. Changes in antimicrobial resistance, serotypes and genotypes in *Streptococcus pneumoniae* over a 30-year period. Clin Microbiol Infect. 2010;16(5):402–10. <https://doi.org/10.1111/j.1469-0691.2010.03182.x>.
 52. Mouz N, Di Guilmi AM, Gordon E, Hakenbeck R, Dideberg O, Vernet T. Mutations in the active site of penicillin-binding protein PBP2x from *Streptococcus pneumoniae*. Role in the specificity for beta-lactam antibiotics. J Biol Chem. 1999;274(27):19175–80. <https://doi.org/10.1074/jbc.274.27.19175>.
 53. Nagai K, Davies TA, Jacobs MR, Appelbaum PC. Effects of amino acid alterations in penicillin-binding proteins (PBPs) 1a, 2b, and 2x on PBP

- affinities of penicillin, ampicillin, amoxicillin, cefditoren, cefuroxime, cefprozil, and cefaclor in 18 clinical isolates of penicillin-susceptible, -intermediate, and -resistant pneumococci. *Antimicrob Agents Chemother.* 2002;46(5):1273–80. <https://doi.org/10.1128/AAC.46.5.1273-1280.2002>.
54. Calvez P, Breukink E, Roper DI, Dib M, Contreras-Martel C, Zapun A. Substitutions in PBP2b from beta-lactam-resistant *Streptococcus pneumoniae* have different effects on enzymatic activity and drug reactivity. *J Biol Chem.* 2017;292(7):2854–65. <https://doi.org/10.1074/jbc.M116.764696>.
 55. Figueiredo TA, Sobral RG, Ludovice AM, Almeida JM, Bui NK, Vollmer W, et al. Identification of genetic determinants and enzymes involved with the amidation of glutamic acid residues in the peptidoglycan of *Staphylococcus aureus*. *PLoS Pathog.* 2012;8(11):e1002508. <https://doi.org/10.1371/journal.ppat.1002508>.
 56. Zapun A, Philippe J, Abrahams KA, Signor L, Roper DI, Breukink E, et al. In vitro reconstitution of peptidoglycan assembly from the Gram-positive pathogen *Streptococcus pneumoniae*. *ACS Chem Biol.* 2013;8(12):2688–96. <https://doi.org/10.1021/cb400575t>.
 57. Kocaoglu O, Tsui HC, Winkler ME, Carlson EE. Profiling of beta-lactam selectivity for penicillin-binding proteins in *Streptococcus pneumoniae* D39. *Antimicrob Agents Chemother.* 2015;59(6):3548–55. <https://doi.org/10.1128/AAC.05142-14>.
 58. Sakoulas G, Moellering RC Jr. Increasing antibiotic resistance among methicillin-resistant *Staphylococcus aureus* strains. *Clin Infect Dis.* 2008; 46(Supplement_5):S360–S7.
 59. Kehrmann J, Kaase M, Szabados F, Gatermann SG, Buer J, Rath PM, et al. Vancomycin MIC creep in MRSA blood culture isolates from Germany: a regional problem? *Eur J Clin Microbiol Infect Dis.* 2011;30(5):677–83. <https://doi.org/10.1007/s10096-010-1140-7>.
 60. van Duijkereen E, Greko C, Pringle M, Baptiste KE, Catry B, Jukes H, et al. Pleuromutilins: use in food-producing animals in the European Union, development of resistance and impact on human and animal health. *J Antimicrob Chemother.* 2014;69(8):2022–31. <https://doi.org/10.1093/jac/dku123>.
 61. Metcalf BJ, Chochua S, Gertz RE Jr, Li Z, Walker H, Tran T, et al. Using whole genome sequencing to identify resistance determinants and predict antimicrobial resistance phenotypes for year 2015 invasive pneumococcal disease isolates recovered in the United States. *Clin Microbiol Infect.* 2016; 22(12):1002.e1–8.
 62. Dunai A, Spohn R, Farkas Z, Lázár V, Györkei Á, Apjok G, et al. Rapid decline of bacterial drug-resistance in an antibiotic-free environment through phenotypic reversion. *Elife.* 2019;8:e47088. <https://doi.org/10.7554/eLife.47088>.
 63. Enne Virve I, Delsol Anne A, Roe John M, Bennett PM. Evidence of antibiotic resistance gene silencing in *Escherichia coli*. *Antimicrob Agents Chemother.* 2006;50(9):3003–10. <https://doi.org/10.1128/AAC.00137-06>.
 64. Kime L, Randall CP, Banda FI, Coll F, Wright J, Richardson J, et al. Transient silencing of antibiotic resistance by mutation represents a significant potential source of unanticipated therapeutic Failure. *mBio.* 2019;10(5): e01755–19.
 65. Zhang Z, Zhai Y, Guo Y, Li D, Wang Z, Wang J, et al. Characterization of unexpressed extended-spectrum beta-lactamase genes in antibiotic-sensitive *Klebsiella pneumoniae* isolates. *Microb Drug Resist.* 2017;24(6):799–806. <https://doi.org/10.1089/mdr.2017.0018>.
 66. O'Neill CE, Seth-Smith HMB, Van Der Pol B, Harris SR, Thomson NR, Cutcliffe LT, et al. *Chlamydia trachomatis* clinical isolates identified as tetracycline resistant do not exhibit resistance in vitro: whole-genome sequencing reveals a mutation in *porB* but no evidence for tetracycline resistance genes. *Microbiology.* 2013;159(Pt_4):748–56.
 67. Vk D, Srikumar S, Shetty S, van Nguyen S, Karunasagar I, Fanning S. Silent antibiotic resistance genes: a threat to antimicrobial therapy. *Int J Infect Dis.* 2019;79:20. <https://doi.org/10.1016/j.ijid.2018.11.063>.
 68. Liu Y, Wang Y, Schwarz S, Wang S, Chen L, Wu C, et al. Investigation of a multiresistance gene *cfr* that fails to mediate resistance to phenicols and oxazolidinones in *Enterococcus faecalis*. *J Antimicrob Chemother.* 2014; 69(4):892–8. <https://doi.org/10.1093/jac/dkt459>.
 69. Li Y, Metcalf BJ, Chochua S, Li Z, Gertz RE Jr, Walker H, et al. Validation of β -lactam minimum inhibitory concentration predictions for pneumococcal isolates with newly encountered penicillin binding protein (PBP) sequences. *BMC Genom.* 2017;18(1):621. <https://doi.org/10.1186/s12864-017-4017-7>.
 70. Beall B, Chochua S, Gertz RE Jr, Li Y, Li Z, McGee L, et al. A population-based descriptive atlas of invasive pneumococcal strains recovered within the U.S. During 2015–2016. *Front Microbiol.* 2018;9:2670.
 71. Varghese J, Chochua S, Tran T, Walker H, Li Z, Snippes Vagnone PM, et al. Multistate population and whole genome sequence-based strain surveillance of invasive pneumococci recovered in the USA during 2017. *Clin Microbiol Infect.* 2020;26(4):512.e1–e10.
 72. Metcalf BJ, Chochua S, Gertz RE Jr, Hawkins PA, Ricaldi J, Li Z, et al. Short-read whole genome sequencing for determination of antimicrobial resistance mechanisms and capsular serotypes of current invasive *Streptococcus agalactiae* recovered in the USA. *Clin Microbiol Infect.* 2017; 23(8):574.e7–e14.
 73. de Jong A, Thomas V, Simjee S, Moyaert H, El Garch F, Maher K, et al. Antimicrobial susceptibility monitoring of respiratory tract pathogens isolated from diseased cattle and pigs across Europe: The VetPath study. *Vet Microbiol.* 2014;172(1):202–15. <https://doi.org/10.1016/j.vetmic.2014.04.008>.
 74. Quail MA, Kozarewa I, Smith F, Scally A, Stephens PJ, Durbin R, et al. A large genome center's improvements to the Illumina sequencing system. *Nat Methods.* 2008;5(12):1005–10. <https://doi.org/10.1038/nmeth.1270>.
 75. Joshi N, Fass J. Sickle: a sliding-window, adaptive, quality-based trimming tool for FastQ files. 2011.
 76. Bankevich A, Nurk S, Antipov D, Gurevich AA, Dvorkin M, Kulikov AS, et al. SPAdes: a new genome assembly algorithm and its applications to single-cell sequencing. *Journal of Computational Biology.* 2012;19(5):455–77. <https://doi.org/10.1089/cmb.2012.0021>.
 77. Seemann T. Prokka: rapid prokaryotic genome annotation. *Bioinformatics.* 2014;30(14):2068–9. <https://doi.org/10.1093/bioinformatics/btu153>.
 78. Wingett SW, Andrews S. FastQ Screen: a tool for multi-genome mapping and quality control. *F1000Res.* 2018;7:1338.
 79. Li H, Durbin R. Fast and accurate short read alignment with Burrows–Wheeler transform. *Bioinformatics.* 2009;25(14):1754–60. <https://doi.org/10.1093/bioinformatics/btp324>.
 80. Cheng L, Connor TR, Sirén J, Aanensen DM, Corander J. Hierarchical and spatially explicit clustering of DNA sequences with BAPS software. *Mol Biol Evol.* 2013;30(5):1224–8. <https://doi.org/10.1093/molbev/mst028>.
 81. R Core Team. R: a language and environment for statistical computing R Foundation for Statistical Computing; 2021.
 82. Page AJ, Cummins CA, Hunt M, Wong VK, Reuter S, Holden MTG, et al. Roary: rapid large-scale prokaryote pan genome analysis. *Bioinformatics.* 2015;31(22):3691–3. <https://doi.org/10.1093/bioinformatics/btv421>.
 83. Ranwez V, Harispe S, Delsuc F, Douzery EJP. MACSE: multiple alignment of coding sequences accounting for frameshifts and stop codons. *PLoS one.* 2011;6(9):e22594. <https://doi.org/10.1371/journal.pone.0022594>.
 84. Paradis E, Claude J, Strimmer K. APE: Analyses of phylogenetics and evolution in R language. *Bioinformatics.* 2004;20(2):289–90. <https://doi.org/10.1093/bioinformatics/btg412>.
 85. Hunt M, Mather AE, Sánchez-Busó L, Page AJ, Parkhill J, Keane JA, et al. ARIBA: rapid antimicrobial resistance genotyping directly from sequencing reads. *Microb Genom.* 2017;3(10):e000131. <https://doi.org/10.1099/mgen.0.000131>.
 86. Lopez P, Espinosa M, Greenberg B, Lacks S. Sulfonamide resistance in *Streptococcus pneumoniae*: DNA sequence of the gene encoding dihydropteroate synthase and characterization of the enzyme. *J Bacteriol.* 1987;169(9):4320–6. <https://doi.org/10.1128/jb.169.9.4320-4326.1987>.
 87. Adrian PV, Klugman KP. Mutations in the dihydrofolate reductase gene of trimethoprim-resistant isolates of *Streptococcus pneumoniae*. *Antimicrob Agents Chemother.* 1997;41(11):2406–13. <https://doi.org/10.1128/AAC.41.11.2406>.
 88. Hakenbeck R, Grebe T, Zähler D, Stock JB. β -Lactam resistance in *Streptococcus pneumoniae*: penicillin-binding proteins and non-penicillin-binding proteins. *Mol Microbiol.* 1999;33(4):673–8. <https://doi.org/10.1046/j.1365-2958.1999.01521.x>.
 89. Edgar RC. MUSCLE: multiple sequence alignment with high accuracy and high throughput. *Nucleic Acids Res.* 2004;32(5):1792–7. <https://doi.org/10.1093/nar/gkh340>.
 90. Gouy M, Guindon S, Gascuel O. SeaView version 4: a multiplatform graphical user interface for sequence alignment and phylogenetic tree building. *Mol Biol Evol.* 2010;27(2):221–4. <https://doi.org/10.1093/molbev/msp259>.
 91. Contreras-Martel C, Dahout-Gonzalez C, Martins Ados S, Kotnik M, Dessen A. PBP active site flexibility as the key mechanism for beta-lactam resistance in

- pneumococci. *J Mol Biol.* 2009;387(4):899–909. <https://doi.org/10.1016/j.jmb.2009.02.024>.
92. Haenni M, Galofaro L, Ythier M, Giddey M, Majcherczyk P, Moreillon P, et al. Penicillin-binding protein gene alterations in *Streptococcus uberis* isolates presenting decreased susceptibility to penicillin. *Antimicrob Agents Chemother.* 2010;54(3):1140–5. <https://doi.org/10.1128/AAC.00915-09>.
 93. Piccinelli G, Carlentini G, Gargiulo F, Caruso A, De Francesco MA. Analysis of point mutations in the pbp2x, pbp2b, and pbp1a genes of *Streptococcus agalactiae* and their relation with a reduced susceptibility to cephalosporins. *Microb Drug Resist.* 2017;23(8):1019–24. <https://doi.org/10.1089/mdr.2017.0013>.
 94. Haroche J, Allignet J, Buchrieser C, El Solh N. Characterization of a variant of vga (A) conferring resistance to streptogramin A and related compounds. *Antimicrob Agents Chemother.* 2000;44(9):2271–5. <https://doi.org/10.1128/AAC.44.9.2271-2275.2000>.
 95. Pikis A, Donkersloot JA, Rodriguez WJ, Keith JM. A conservative amino acid mutation in the chromosome-encoded dihydrofolate reductase confers trimethoprim resistance in *Streptococcus pneumoniae*. *J Infect Dis.* 1998; 178(3):700–6. <https://doi.org/10.1086/515371>.
 96. Bergmann R, van der Linden M, Chhatwal GS, Nitsche-Schmitz DP. Factors that cause trimethoprim resistance in *Streptococcus pyogenes*. *Antimicrob Agents Chemother.* 2014;58(4):2281–8. <https://doi.org/10.1128/AAC.02282-13>.
 97. Athey TBT, Teatero S, Lacouture S, Takamatsu D, Gottschalk M, Fittipaldi N. Determining *Streptococcus suis* serotype from short-read whole-genome sequencing data. *BMC Microbiol.* 2016;16(1):162.
 98. Team RC. R: A language and environment for statistical computing. 2013.
 99. Pinheiro J, Bates D, DebRoy S, Sarkar D, Heisterkamp S, Van Willigen B, et al. Package 'nlme'. 2019.
 100. *Streptococcus suis* Genome sequencing and assembly. NCBI BioProject accession PRJNA628943. 2020. <https://www.ncbi.nlm.nih.gov/bioproject/?term=PRJNA628943>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.